Supplementary Table 1. Genotype frequencies of *p53* Arg72Pro in HBV patients and healthy subjects

	Patients with HBV infection							Healthy subjects (n=96)[a]
	Total patients (*n*=580)[a]	HCC (*n*=350)[a]	Non-HCC (*n*=230)[a]	Crude OR (95% CI) HCC versus Non-HCC	P-value	Adjusted OR(95% CI) HCC versus Non-HCC[b]	P-value	
Genotype								
Arg/Arg	189 (32.59)	103 (29.43)	86 (37.39)	1		1		32 (33.34)
Arg/Pro	283 (48.79)	174 (49.71)	109 (47.39)	1.33(0.92-1.94)	0.131	1.41 (0.92-2.16)	0.112	50 (52.08)
Pro/Pro	108 (18.62)	73 (20.86)	35 (15.22)	1.74 (1.06-2.85)	**0.028**	1.88 (1.07-3.32)	**0.029**	14 (14.58)
Recessive model								
Arg/Arg+Arg/Pro	472 (81.38)	277 (79.14)	195 (84.78)	1		1		82 (85.42)
Pro/Pro	108 (18.62)	73 (20.86)	35 (15.22)	1.47 (0.94-2.29)	0.089	1.53 (0.92-2.54)	0.100	14 (14.58)
Dominant model								
Arg/Arg	189 (32.59)	103 (29.43)	86 (37.39)	1		1		32 (33.34)
Arg/Pro+Pro/Pro	391 (67.41)	247 (70.57)	144 (62.61)	1.432 (1.01-2.04)	0.046	1.52(1.02-2.28)	0.040	64 (66.66)

[a] Values expressed as n (%).

[b] Adjusted for gender, age, and alpha-fetoprotein level.

Supplementary Table 2. Genotype frequencies of MDM2 SNP 309 in HBV patients and healthy subjects.

	Patients with HBV infection							Healthy subjects (n=96)[a]
	Total patients (*n*=580)[a]	HCC (*n*=350)[a]	Non-HCC (*n*=230)[a]	Crude OR (95% CI) HCC versus Non-HCC	P-value	Adjusted OR(95% CI) HCC versus Non-HCC[b]	P-value	
Genotype								
T/T	148(25.52)	89(25.43)	59(25.65)	1		1		19 (19.79)
T/G	292(50.34)	176(50.29)	116(50.43)	1.01(0.67-1.51)	0.978	0.94(0.59-1.48)	0.777	49 (51.04)
G/G	140(24.14)	85(24.28)	55(23.92)	1.03(0.64-1.64)	0.920	1.12(0.65-1.93)	0.685	28 (29.17)
Recessive model								
T/T+T/G	440(75.86)	265(75.71)	175(76.08)	1		1		68 (70.83)
G/G	140(24.14)	85(24.29)	55(23.92)	1.02(0.69-1.51)	0.918	1.17(0.743-1.84)	0.500	28 (29.17)
Dominant model								
T/T	148(25.52)	89(25.43)	59(25.65)	1		1		19 (19.79)
T.G+G/G	432(74.48)	261(74.57)	171(74.35)	1.01(0.69-1.48)	0.952	0.99 (0.64-1.53)	0.968	77 (80.21)

[a] Values expressed as n(%).

[b] Adjusted for gender, age, and alpha-fetoprotein level.